0
0
January 14, 2026
SOLANA BEACH, CA — In a landmark decision for the rare disease community, the U.S. Food and Drug Administration (FDA) has approved Zycubo (copper histidinate) as the first and only treatment for pediatric patients with Menkes disease. The approval, announced late Monday, provides a critical lifeline for families battling this ultra-rare and historically fatal genetic disorder, which often claims the lives of children before their third birthday.
A Devastating Deficit
Menkes disease, sometimes called “kinky hair disease” due to the characteristic brittle, silver-colored hair of affected infants, is a neurodegenerative disorder caused by mutations in the ATP7A gene. This gene is responsible for regulating copper levels in the body. In children with Menkes, the body can take in copper from food, but it cannot move it out of the intestines and into the bloodstream or across the blood-brain barrier.
Without copper—a vital cofactor for enzymes that build bone, cartilage, and brain tissue—the body begins to shut down. Infancy is typically marked by seizures, low muscle tone (hypotonia), and significant developmental delays.
“Children with this devastating, degenerative disease will finally have an FDA-approved treatment option and the potential to live longer,” said Christine Nguyen, MD, deputy director of the Office of Rare Diseases in the FDA’s Center for Drug Evaluation and Research (CDER).
The Evidence: Rewriting the Prognosis
The FDA’s approval was based on a pooled analysis of two open-label clinical trials. Researchers compared the survival rates of patients treated with Zycubo to a historical “control group” of untreated patients.
The results were stark. For infants who began treatment within the first four weeks of life (the “early treatment” group):
-
78% Reduction in Risk: Patients saw a nearly 80% lower risk of death compared to untreated children.
-
Median Survival: The median overall survival for the early-treatment group was 177.1 months (nearly 15 years), compared to just 16.1 months for the untreated group.
-
Long-Term Survival: Nearly half of the treated patients survived beyond six years, and some survived past age 12. In the untreated group, no patients survived beyond age six.
Even for children who began treatment after the four-week window, a “substantial survival benefit” was observed, though experts emphasize that early intervention is the key to preventing irreversible neurological damage.
How Zycubo Works
Zycubo is a bioavailable copper replacement therapy administered via a daily subcutaneous injection. By injecting the copper histidinate directly under the skin, the treatment bypasses the gastrointestinal tract—where the genetic “blockade” occurs—allowing copper to enter the bloodstream directly.
“This milestone represents the culmination of decades of research,” said Dr. Stephen Kaler, a clinical genetics specialist at Columbia University Medical Center who has studied Menkes for years. “Beginning copper histidinate therapy in affected neonates has been shown to reduce symptoms and prolong life, but we must pair this treatment with increased awareness and rapid testing.”
Navigating the Risks: A Delicate Balance
While Zycubo offers hope, it is not a cure, and it requires vigilant medical management. Because the body cannot naturally regulate the copper provided by the injection, there is a risk of copper toxicity.
The FDA warned that copper can accumulate in the kidneys and liver, potentially leading to organ dysfunction. Common side effects observed in the trials included:
-
Respiratory infections and pneumonia
-
Seizures
-
Vomiting and fever
-
Anemia
-
Injection site reactions
Physicians will need to perform regular blood tests and organ function screenings to ensure copper levels remain within a safe therapeutic window.
The Path to Approval
The road to Monday’s approval was not without hurdles. Sentynl Therapeutics, the manufacturer, initially faced a setback last year when the FDA issued a “complete response letter” citing manufacturing issues. After revising its application and addressing those concerns, the company resubmitted its New Drug Application (NDA) in November.
The FDA’s early approval—coming two days before its official January 14 deadline—underscores the agency’s recognition of the urgent unmet need. “The company demonstrated a large improvement in overall survival using an innovative trial design that addressed the challenges of studying an ultra-rare disease,” noted Tracy Beth Hoeg, MD, PhD, acting director of CDER.
What This Means for Families
For parents of newborns showing early signs of Menkes, the approval shifts the conversation from palliative care to active management. However, the drug is specifically indicated for Menkes disease and is not currently approved for Occipital Horn Syndrome (OHS), a milder form of the disorder.
Public health advocates are now turning their attention to newborn screening. Because the most significant benefits are seen when treatment starts within 28 days of birth—often before symptoms like “kinky hair” appear—identifying the genetic mutation at birth could be the difference between life and death.
References
- https://www.medscape.com/viewarticle/fda-approves-first-treatment-menkes-disease-children-2026a100017p
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
